Stockscreener 앱 받기
65.53
1.58%
-1.01
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference - Bitget
BridgeBio Pharma to Present Phase 3 FORTIFY Trial Data on LGMD2I/R9 Therapy at 2026 MDA Conference - geneonline.com
BridgeBio to present LGMD2I/R9 trial data at MDA conference By Investing.com - Investing.com Australia
[144] BridgeBio Pharma, Inc. SEC Filing - Stock Titan
BridgeBio to present LGMD2I/R9 trial data at MDA conference - Investing.com Nigeria
TD Asset Management Inc Purchases Shares of 88,950 BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Latest Stock News & Headlines - Yahoo Finance
BridgeBio Pharma to Present New Data on BBP-418 for LGMD2I/R9 at MDA Conference - Quiver Quantitative
BridgeBio muscular dystrophy trial hits key goals in Phase 3 study - Stock Titan
Aisling Capital Management LP Has $316.29 Million Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma Director Sells Shares - TradingView
BridgeBio (BBIO) director sells 25,484 shares after option exercise - Stock Titan
BBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rafferty Asset Management LLC Sells 44,792 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success - Bitget
Intech Investment Management Trims BridgeBio Pharma Stake - National Today
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Unpacking a 50.49% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Intech Investment Management LLC Sells 19,826 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Is BridgeBio Pharma (BBIO) Attractive After Recent Pullback And Late Stage Pipeline Progress? - Yahoo Finance
Okabena Investment Services Inc. Makes New $816,000 Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Monashee Investment Management LLC Lowers Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
ETFs investiert in BridgeBio Pharma, Inc.-Aktien - TradingView
Fox Run Management L.L.C. Reduces Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Insider Sell: Maricel Apuli Sells 2,000 Shares of BridgeBio Phar - GuruFocus
What BridgeBio Pharma (BBIO)'s Surging 2025 Revenue and Growing Losses Means For Shareholders - simplywall.st
BridgeBio (BBIO) CAO sells 2,000 shares in Rule 10b5-1 trade - Stock Titan
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), BridgeBio Pharma (BBIO) and Establishment Labs Holdings (ESTA) - The Globe and Mail
BridgeBio Pharma Earnings Call Signals Profitable Pivot - TipRanks
BridgeBio Pharma (BBIO) Analyst Rating Update: Oppenheimer Lowers Price Target | BBIO Stock News - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Trading Down 6.7% on Disappointing Earnings - MarketBeat
BridgeBio Pharma (BBIO): Today's Analyst Rating Update | BBIO St - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $95.00 at Truist Financial - MarketBeat
Oppenheimer Issues Pessimistic Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
BridgeBio Pharma (BBIO) Receives Analyst Rating and Price Target Update | BBIO Stock News - GuruFocus
Morgan Stanley Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
BridgeBio Pharma (BBIO): Evercore ISI Group Raises Price Target to $125 | BBIO Stock News - GuruFocus
Oppenheimer Adjusts Price Target on BridgeBio Pharma to $81 From $83, Maintains Outperform Rating - marketscreener.com
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q4 2025 Earnings Call Transcript - Insider Monkey
BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside - TipRanks
BridgeBio Pharma Reports Narrower Net Loss For Q4, Revenue Zooms On Attruby Sales - RTTNews
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: St - GuruFocus
BridgeBio Pharma earnings missed by $0.28, revenue topped estimates - Investing.com Australia
Decoding BridgeBio Pharma Inc (BBIO): A Strategic SWOT Insight - GuruFocus
BridgeBio Pharma (BBIO) Projects Strong Cash Flow by 2028 - GuruFocus
BridgeBio Pharma, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript - AOL.com
BridgeBio Pharma Q4 Earnings Call Highlights - MarketBeat
BridgeBio rises on revenue beat despite wider loss - Investing.com South Africa
BridgeBio (BBIO) Exceeds Revenue Expectations in Q4 - GuruFocus
BridgeBio Pharma (NASDAQ: BBIO) grows ATTR franchise and advances three Phase 3 drugs - Stock Titan
BridgeBio Pharma: Fourth Quarter Financial Highlights - Bitget
BridgeBio Pharma (NASDAQ:BBIO) Posts Quarterly Earnings Results, Misses Expectations By $0.25 EPS - MarketBeat
BridgeBio Pharma: Q4 Earnings Snapshot - marketscreener.com
Earnings Flash (BBIO) BridgeBio Pharma Posts Q4 Loss $1, vs. FactSet Est of $0.71 Loss - marketscreener.com
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates - The Manila Times
BridgeBio Pharma Earnings Review: Q4 Summary - Benzinga
BridgeBio (NASDAQ: BBIO) doubles 2025 revenue to $502M but posts $725M loss - Stock Titan
Three late-stage drug wins move BridgeBio toward six genetic treatments - Stock Titan
BridgeBio Pharma, Inc. announced that its investigational drug Encaleret for ADH1 (Autosomal Dominant Hypocalcemia Type 1) achieved positive results in the Phase 3 CALIBRATE clinical trial. - Bitget
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 28,053 Shares of Stock - MarketBeat
BridgeBio Pharma CEO Neil Kumar Sells Shares - TradingView
BridgeBio Pharma (NASDAQ: BBIO) CEO logs 28,053-share sale under Rule 10b5-1 plan - Stock Titan
4.32%
자본화:
|
볼륨(24시간):